T cell leukemia control via Ras-Raf pathway inhibition with peptides

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The RAS-RAF-MEK-ERK pathway is a key target in anticancer therapy.
• Tumor resistance can arise from N-Ras hyperactivation, necessitating novel therapeutic strategies.
• Peptides designed to inhibit Ras/Raf interaction exhibit pro-apoptotic properties.

Purpose of the Study:

• To evaluate the anti-tumoral efficacy of WO2015001045 A2 peptides.
• To assess the impact of these peptides on survival in a spontaneous leukemia model.

Main Methods:

• BALB/c mice with LB leukemia were randomly assigned to control (placebo) or treatment groups.
• Treatment involved daily administration of 3 mg/kg of peptide for 30 days.
• Survival rates and malignant T cell presence in organs were monitored.

Main Results:

• 100% survival in the treatment group by day 15 versus 24% in the control group.
• Average survival increased from 15.48 days (control) to 20.27 days (treated).
• Reduced malignant T cell infiltration was observed in bone marrow, spleen, and lymph nodes of treated mice.

Conclusions:

• WO2015001045 A2 peptides significantly improve survival in a murine model of spontaneous T lymphoid leukemia.
• These peptides represent a potential therapeutic option for controlling malignant lymphoproliferative diseases.